Loading...

drthomas123's Message Board Messages

Loading...
Showing 1 - 10 of 6

Page 1 of 1

PROBLEM: Not all cancer cells can be induced to undergo apoptosis (programmed cell death). Even when they do, the mere act of apoptosis can trigger the proliferation of cancer stem cells. Cancer stem cells can lead to distant metastasis, treatment failure, and disease recurrence. SOLUTION: Target cancer stem cells by directly killing them and/or preventing them from entering a dormant and more resistant state. PROBLEM: Instead of apoptosis, some cancer cells can be induced to enter a senescent or dormant state. Fortunately, senescent cancer cells permanently stop dividing, but unfortunately, they don’t die. They maintain cellular metabolism. This metabolism leads to the secretion of pro-inflammatory, cancer-causing compounds (also known as the “senescent secretome”). If enough senescent cancer cells accumulate, this can induce further growth and spread of cancer. SOLUTION: Target accumulated senescent cancer stem cells by directly killing them and/or keep the senescence secretome under control.

To simultaneously kill bulk tumor cells and cancer stem cells, the most potent treatment I offer is high-dose intravenous vitamin C (sodium ascorbate) augmented with artesunate, azithromycin, and doxycycline, and electrolytically balanced with magnesium chloride, potassium chloride, and calcium chloride. The anti-cancer effect is further increased by the addition of intravenous plant flavonoids (epigallocatechin-3-gallate, luteolin, and quercetin) that inhibit the protective antioxidant defense mechanisms of cancer, and induce systemic vasodilation leading to enhanced permeability and retention of the vitamin C in dense tumor tissue.

Because of the unique bi-oxidant properties of vitamin C, at low (oral) doses, it works as a potent antioxidant that reduces oxidative stress. However, at high (intravenous) doses, vitamin C becomes a potent pro-oxidant “drug” that induces severe oxidative stress in cancer cells through the formation of cytotoxic levels of hydrogen peroxide. Hydrogen peroxide is highly toxic to all cells, however, normal cells have higher levels of the enzyme catalase which neutralizes hydrogen peroxide. Cancer cells have 10 to 100 times less catalase than normal cells. The hydrogen peroxide produced by high-dose intravenous vitamin C cannot be fully neutralized by cancer cells.

There is a large volume of published studies documenting the use of intravenous vitamin C for cancer. There is ample evidence that not only is it safe and effective along with conventional cancer treatment, but high-dose intravenous vitamin C can also be regarded as a stand-alone “chemotherapy” agent, killing cancer cells through the well defined pro-oxidative mechanism described above (click here for more information).

High-dose intravenous vitamin C targets the underlying pathologies that lead to the formation and spread of cancer. The addition of artesunate and plant flavonoids potentiates (amplifies) the anti-cancer effects of vitamin C. The addition of azithromycin and doxycycline targets cancer stem cells. And the addition of magnesium chloride, potassium chloride, and calcium chloride prevents harmful electrolyte imbalances during treatment. Through the following mechanisms, this potent and synergistic combination exploits vulnerable metabolic and signaling pathways of cancer, creates a cellular environment that is hostile to cancer, and compromises cancer’s ability to survive while improving quality of life:

  • Induces oxidative stress by generating toxic levels of hydrogen peroxide selectively targeting cancer cells
  • Lowers the catalase, glutathione, and thioredoxin reductase pool in cancer cells, leading to further oxidative stress and apoptosis
  • Inhibits glycolysis by targeting the activity of GAPDH, a key glycolytic enzyme
  • Relieves cellular hypoxia and helps restore normal aerobic respiration by oxidizing NADH to NAD in the Krebs cycle
  • Downregulates the pentose phosphate pathway and the ability of cancer to generate nucleic acids (DNA & RNA) and fatty acids needed to generate new cancer cells
  • Increases electron flux through the mitochondrial electron transport chain
  • Activates cancer-suppressor p53 protein to help restore normal apoptosis in cancer cells
  • Reduces the production of inflammatory cytokines
  • Neutralizes DNA-damaging free radicals
  • Inhibits angiogenesis and reduces tumor blood supply
  • Removes the protective shield (cloak) safeguarding cancer cells and makes them vulnerable to immune cells
  • Eradicates cancer stem cells
  • Supports detoxification systems in the body
  • Promotes the formation of collagen to wall off tumors
  • Inhibits hyaluronidase to retard metastasis
  • Reduces pain and increases energy
  • Renders cancer more vulnerable to the anti-cancer effects of chemotherapy and radiation while protecting normal cells from the side effects

Our intravenous vitamin C treatment takes 3½ hours. We administer treatment for 7 days in a row, once per month, for 6-12 months. This follows the “Press-Pulse” (on-off/weaken-kill) concept elucidated by renowned cancer biologist Dr. Thomas Seyfried (click here). Diet, meal timing, exercise, targeted supplements, and repurposed medications are designed to weaken the bulk tumor cells and cancer stem cells through starvation, and the intravenous treatment is designed to kill the weakened cells. This repeating “weaken-and-kill” cycle is powerful. Progress is monitored using tumor markers and/or scans every 3 months.

On Mar 10, 2019 8:49 PM Swifty wrote:

What type of cancer are you treating with the LDN? I was on it for a few years for Hashimoto's and went off at Doctor's suggestion. Now it appears I likely have thyroid cancer. I wonder if I should go back on before all the testing and Dr. appointments or wait.

Unless a patient is on opiates for pain, I use low-dose naltrexone (LDN) on almost all of my cancer patients. Without the benefit of knowing your complete medical history, physical findings, lab work, etc., I cannot advise in your particular situation.

Hello, I treat my patients of Glioblastoma Multiforme with the following options:

Care Oncology: http://www.careoncology.com
Syrosingopine: https://edoc.unibas.ch/54765/1/e1601756.full.pdf
Perillyl alcochol: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769394/pdf/ol-
Gallium maltolate: https://www.gallixa.com/GAMReferences/chitambaretal2018.pdf

you or anyone looking for second opinion for treatment of GBM can contact me anytime

Cancer is a serious and terrifying disease. If you have been diagnosed with cancer, your mind is probably filled with fear, worry, and questions. Therefore, it is important to talk openly and frankly with your oncologist. And to better understand your cancer and your treatment options, it is imperative to know WHAT to ask. If you are determined to beat this disease, here are the top 10 questions you MUST ask your oncologist: What is the rationale for your recommended treatment and is your expectation for me curative (achieving long-term remission) or pallia­tive (improving quality of life)? What might my overall survival time be if I follow your recommendations compared to not following your recommendations? How many of the following hallmarks of cancer will you be targeting: a) Genetic instability, b) sustained proliferation, c) replicative immortality, d) dysregulated metabolism, e) evading growth suppressors, f) resisting cell death, g) tumor-promoting inflammation, h) angiogenesis, i) tissue invasion and metastasis, and j) immune evasion? What are the likely side effects of treatment and how will you deal with each of them? How do you plan to prevent damage to the DNA and mitochondria of my normal (healthy) cells? Find more at http://www.thomashealthblog.com/?p=5550
Showing 1 - 10 of 6

Page 1 of 1

Loading...

About drthomas123

drthomas123 has not shared any information about themselves. Send them a message to tell them you'd like to find out more about them or add them as a friend.

We care about your feedback. Let us know how we can improve your CancerCompass experience.